Hospital 9 De Octubre S.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The urology department at Hospital 9 De Octubre is extending its expertise to address elevated Lipoprotein(a) and its role in atherosclerotic cardiovascular disease, aiming to lower the risk of major cardiac events.
- Lipoprotein(a)–targeted RNA therapeutics
- Reduction of major adverse cardiovascular events
- Cardiovascular risk stratification in high‑risk patients
- Evaluation of novel lipid‑lowering strategies
Across two clinical studies, nine investigators are testing innovative approaches to improve heart health, with a focus on safety, efficacy, and long‑term outcomes.
Neoplasms
Research in the oncology field concentrates on metastatic non‑small cell lung cancer and non‑muscle invasive bladder cancer, evaluating new immunotherapy combinations and device‑assisted drug delivery to enhance survival and disease control.
- Immune‑checkpoint inhibitor combinations with chemotherapy
- Intravesical electroporation of mitomycin C
- Adjuvant strategies for high‑grade bladder tumors
- Biomarker‑driven treatment optimization
Six trials involve multidisciplinary teams, seeking to broaden therapeutic options for patients with advanced lung and bladder cancers while maintaining safety standards.
Bacterial Infections and Mycoses
The site is conducting pediatric vaccine research focused on the pentavalent meningococcal ABCYW vaccine, assessing its safety and immune response in children, toddlers, and infants to prevent meningococcal disease.
- Safety profiling across pediatric age groups
- Immunogenicity against serogroups A, C, W‑135, Y, and B
- Comparative analysis with existing meningococcal vaccines
- Long‑term antibody persistence evaluation
These investigations involve multiple stages of enrollment, aiming to provide robust protection for young populations while informing future immunization strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Gilead Sciences Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital 9 De Octubre S.A.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer | Gilead Sciences Inc. | Phase II | Not Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 2 | Unknown | 2022-12-01 | 2024-03-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.